Transplantation psychoneuroimmunology: Building hypotheses

Medical Hypotheses

Volumn 54, Issue 6, 2000, Pages 969-978

  Klapheke, M M ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

CORONARY ARTERY DISEASE; DEPRESSION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL LITERATURE; NATURAL KILLER CELL; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE; THEORY; TRANSPLANTATION;

EID: 0033936604     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0998     Document Type: Article

References (56)

1. Newport D. J., Nemeroff C. B. Assessment and treatment of depression in the cancer patient. J Psychosom Res. 45:1998;215-237.
2. Buckingham J. C., Gillies G. E., Cowell A. Stress, Stress Hormones and the Immune System, 1998;John Wiley & Sons, Chichester.
3. Esterling B., Antoni M., Kumar M., Schneiderman N. Emotional repression, stress disclosure responses, and Epstein-Barr viral capsid antigen titers. Psychosom Med. 52:1990;397-410.
4. Bernstein M., Morrison M. Psychoneuroimmunology: an overview for clinicians caring for cancer and HIV patients. Medicine & Psychiatry. 1:1998;100-111.
5. Solano L., Costa M., Salvati S. Psychosocial factors and clinical evolution in HIV-1 infection: a longitudinal study. J Psychosom Res. 37:1993;39-51.
6. Leserman J., Jackson E., Petitto J. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 61:1999;397-406.
7. Auchincloss H. Immunologic issues in clinical transplantation. Bach F. H., Auchincloss H. Transplantation Immunology. 1995;131-145 Wiley-Liss, New York.
8. Fishman F., Rubin R. Infection in organ-transplant recipients. N Engl J Med. 338:1998;1741-1751.
9. Esterling B., Kiecolt-Glaser J., Glaser R. Psychosocial modulation of cytokine-induced natural killer cell activity in older adults. Psychosom Med. 58:1996;264-272.
10. Herbert T., Cohen S. Stress and immunity in humans: a meta-analytic review. Psychosom Med. 55:1993;364-379.
11. Kronfol Z., Silva J., Greden J., Dembinski S., Gardner R., Carroll B. Impaired lymphocyte function in depressive illness. Life Sci. 33:1983;241-247.
12. Singer A., Bach F. H. Allograft immunity: in vitro and in vivo studies. Bach F. H., Auchincloss H. Transplantation Immunology. 1995;105-111 Wiley-Liss, New York.
13. Schleifer S., Keller S., Camerino M., Thornton J., Stein M. Suppression of lymphocyte stimulation following bereavement. JAMA. 250:1983;374-377.
14. Schleifer S., Keller S., Siris S., Davis K., Stein M. Depression and immunity. Archiv Gen Psychiat. 42:1985;129-133.
15. Schleifer S., Keller S., Bond R., Cohen J., Stein M. Major depressive disorder and immunity. Archiv Gen Psychiat. 46:1989;81-87.
16. Herbert T., Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull. 113:1993;472-486.
17. Schlebusch L., Pillay B., Louw J. Depression and self-report disclosure after live related donor and cadaver renal transplants. S Afr Med J. 75:1989;490-493.
18. Iwashige T., Inoue K., Nakajima T. Renal transplanation: psychiatric aspects and interventions. Jpn J Psychiatry Neurol. 44:1990;7-18.
19. Fukunishi I. Psychosomatic problems surrounding kidney transplantation: incidence of alexithymia and psychiatric disturbances. Psychother Psychosom. 57:1992;42-49.
20. Kober B., Kuchler T., Broelsch C., Kremer B., Henne-Bruns D. A psychological support concept and quality of life research in a liver transplantation program: an interdisciplinary multicenter study. Psychother Psychosom. 54:1990;117-131.
21. Fisher D., Lake K., Reutzel T., Emery R. Changes in health-related quality of life and depression in heart transplant recipients. J Heart Lung Transplant. 14:1995;373-381.
22. Hilbrands L., Hoitsma A., Koene R. The effect of immunosuppressive drugs on quality of life after renal transplantation. Transplantation. 59:1995;1263-1270.
23. Deshields T., McDonough E., Mannen R., Miller L. Psychological and cognitive status before and after heart transplantation. General Hospital Psychiatry. 18:1996;62S-69S.
24. United Network for Organ Sharing Update, March, 1999;. p. 1, 5.
25. Jung W., Irwin M. Reduction of natural killer cytotoxic activity in major depression: interaction between depression and cigarette smoking. Psychosom Med. 61:1999;263-270.
26. Aspinall R. Methods for monitoring immune function. C. .Buckingham J., Gillies G. E., Cowell A. Stress, Stress Hormones and the Immune System. 1997;173-195 John Wiley & Sons, Chichester.
27. Arora P. Neuromodulation of natural killer cell activity. Goetzl E. J., Spector N. H. Neuroiommune Networks: Physiology and Diseases. 1989;39-49 Alan R Liss, Inc. New York.
28. McGee R., Williams S., Elwood M. Depression and the development of cancer: A meta-analysis. Soc Si Med. 38:1994;187-192.
29. Levy S., Herberman R., Whiteside T., Sanzo K., Lee J., Kirkwood J. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. Psychosom Med. 52:1990;73-85.
30. Levy S., Herberman R., Lippman M., D'Angelo T., Lee J. Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behavioral Medicine. 17:1991;67-75.
31. Fawzy F., Kemeny M., Fawzy N. A structured psychiatric intervention for cancer patients. II. Changes over time in immunological measures. Archiv Gen Psychiat. 47:1990;729-735.
32. Spiegel D., Bloom J., Kraemer H., Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. October 14, 1989;888-891.
33. Fawzy F., Fawzy N., Hyun C. Malignant melanoma: effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Archiv Gen Psychiat. 50:1993;681-689.
34. Fawzy F., Cousins N., Fawzy N., Kemeny M., Elashoff R., Morton D. A structured psychiatric intervention for cancer patients: I. Changes over time in methods of coping and affective disturbance. Archiv Gen Psychiat. 47:1990;720-725.
35. Kiecolt-Glaser J., Glaser R. Psychoneuroimmunology and immunotoxicology: implications for carcinogenesis, editorial comment. Psychosom Med. 61:1999;271-272.
36. Glassman A., Shapiro P. Depression and the course of coronary artery disease. Am J Psychiatry. 155:1998;4-11.
37. Herrmann G., Simon R., Haverich A. Left ventricular function, tricuspid incompetence, and incidence of coronary artery disease late after orthotopic heart transplantation. Eur J Cardiothorac Surg. 3:1989;111-118.
38. Straka F., Malek I., Stanek V. Coronary disease in patients after heart transplantation. Cor Vasa. 35:1993;267-275.
39. Schroeder J., Gao S. Calcium blockers and atherosclerosis: lessons from the Standford Transplant Coronary Artery Disease/Diltiazem Trial. Can J Cardiol. 11:1995;710-715.
40. Argenziano M., Michler R., Rose E. Cardiac transplantation for endstage heart disease. Heart Vessels. (Suppl) 12:1997;23-27.
41. Mattila S., Heikkila L., Sipponen J. Heart transplantation in Finland 1985-1995. Ann Chir Gynaecol. 86:1997;113-120.
42. Ferry B., Welsh K., Dunn M. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol. 5:1997;17-24.
43. Ballantyne C., Bourge R., Domalik L. Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry. Am J Cardiol. 78:1996;532-535.
44. Boubenider S., Hiesse C., Goupy C., Kriaa F., Marchand S., Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol. 10:1997;136-145.
45. Kennedy S. Herpes virus infections and psychoneuroimmunology. Friedman H., Klein T., Friedman A. Psychoneuroimmunology, Stress and Infection. 1996;231-242 CRC Press, Boca Raton.
46. Song C., Dinan T., Leonard B. E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. Journal Affective Disorders. 30:1994;283-288.
47. Maes M., Smith R., Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression, invited editorial. Psychoneuroendocrinol. 20:1994;111-116.
48. Sluzewska A., Rybakowski J., Bosmans E. Indicators of immune activation in major depression. Psychiatry Research. 64:1996;161-167.
49. Amsterdam J., Henle W., Winokur A., Wolkowitz O., Pickar D., Paul S. Serum antibodies to Epstein-Barr virus in patients with major depressive disorder. Am J Psychiat. 143:1986;1593-1596.
50. Maes M., Bosmans E., Suy E., Vandervorst C., Dejonckheere C., Raus J. Antiphospholipid, antinuclear, Epstein-Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients. J Affect Disord. 21:1991;133-140.
51. Praus D., Brown G., Rundell J., Paolucci S. Associations between cerebrospinal fluid parameters and high degrees of anxiety or depression in United States Air Force personnel infected with human immunodeficiency virus. J Nerv Ment Dis. 178:1990;392-395.
52. Allen A., Tilkian S. Depression correlated with cellular immunity in systemic immunodeficient Epstein-Barr virus syndrome (SIDES). Journal Clinical Psychiatry. 47:1986;133-135.
53. Cappel R., Gregoire F., Thiry L., Sprecher S. Antibody and cell-mediated immunity to herpes simplex virus in psychotic depression. Journal Clinical Psychiatry. 39:1978;266-268.
54. Kiecolt-Glaser J., Dura J., Speicher C., Trask J., Glaser R. Spousal caregivers of dementia victims: longitudinal changes in immunity and health. Psychosomatic Medicine. 53:1991;345-362.
55. Kennedy S., Kiecolt-Glaser J., Glaser R. Immunological consequences of acute and chronic stressors: mediating role of interpersonal relationships. Br J Med Psychol. 61:1988;77-85.
56. Solomon G. F. Clinical and social implications of stress-induced neuroendocrine-immune interactions. Buckingham J. C., Gillies G. E., Cowell A. Stress, Stress Hormones and the Immune System. 1997;385-401 John Wiley & Sons, Chichester.